HCmed Innovations Co., Ltd. (TPE:6934)

Taiwan · Delayed Price · Currency is TWD

74.20

+1.10 (1.50%)

At close: Aug 25, 2026

15.04% (1Y)

Market Cap	2.67B +26.6%
Revenue (ttm)	109.19M -18.3%
Net Income	-124.61M
EPS	-3.66
Shares Out	35.97M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19,532
Open	72.50
Previous Close	73.10
Day's Range	71.90 - 74.30
52-Week Range	61.60 - 175.00
Beta	1.50
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About HCmed Innovations

HCmed Innovations Co., Ltd. designs, develops, manufactures, and sells respiratory drug delivery systems in the United States, Europe, Africa, and Asia. The company’s products include Pulmogine, a vibrating mesh nebulizer to nebulize a range of liquid medications to treat respiratory diseases and their symptoms in children and adults; and AdheResp, a breath-actuated mesh nebulizer for consumers and healthcare professionals. It also provides intellectual property, advanced technology, customization platforms, manufacturing and commercialization,... [Read more]

Industry Surgical and Medical Instruments and Apparatus

Founded 2014

Country Taiwan

Stock Exchange Taiwan Stock Exchange

Ticker Symbol 6934

Full Company Profile

Financial Performance

In 2025, HCmed Innovations's revenue was 100.23 million, a decrease of -29.22% compared to the previous year's 141.61 million. Losses were -126.11 million, 61.2% more than in 2024.

Financial Statements